Literature DB >> 20425582

The contribution of enteroinsular hormones to the pathogenesis of type 2 diabetes mellitus.

Dima L Diab1, David A D'Alessio.   

Abstract

The gastrointestinal hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), termed incretins, are essential regulators of normal glucose homeostasis. Research indicates that the incretin effect is impaired in type 2 diabetes, and this seems to be a consequence rather than a cause of type 2 diabetes. This review describes the defects in the incretin system seen in diabetic patients and discusses the potential roles of GIP and GLP-1 in the pathogenesis of type 2 diabetes. In addition, new information on clinical applications that exploit the enteroinsular axis to control blood glucose is discussed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20425582     DOI： 10.1007/s11892-010-0114-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


  57 in total

1.  Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

Authors:  Dennis Kim; Leigh MacConell; Dongliang Zhuang; Prajakti A Kothare; Michael Trautmann; Mark Fineman; Kristin Taylor
Journal:  Diabetes Care       Date:  2007-03-12       Impact factor: 19.112

2.  Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

Authors:  M Tang-Christensen; P J Larsen; R Göke; A Fink-Jensen; D S Jessop; M Møller; S P Sheikh
Journal:  Am J Physiol       Date:  1996-10

Review 3.  Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.

Authors:  Michael A Nauck; Birgit Baller; Juris J Meier
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

4.  Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.

Authors:  T Vilsbøll; B Brock; H Perrild; K Levin; H-H Lervang; K Kølendorf; T Krarup; O Schmitz; M Zdravkovic; T Le-Thi; S Madsbad
Journal:  Diabet Med       Date:  2008-01-14       Impact factor: 4.359

5.  Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells.

Authors:  Elizabeth J Abraham; Colin A Leech; Julia C Lin; Henryk Zulewski; Joel F Habener
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

6.  The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

Authors:  Lise L Kjems; Jens J Holst; Aage Vølund; Sten Madsbad
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

7.  Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.

Authors:  T Vilsbøll; H Agersø; T Krarup; J J Holst
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

8.  Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Authors:  P V Højberg; T Vilsbøll; R Rabøl; F K Knop; M Bache; T Krarup; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2008-11-27       Impact factor: 10.122

9.  Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.

Authors:  Kirsten Vollmer; Jens J Holst; Birgit Baller; Mark Ellrichmann; Michael A Nauck; Wolfgang E Schmidt; Juris J Meier
Journal:  Diabetes       Date:  2007-12-05       Impact factor: 9.461

Review 10.  RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes.

Authors:  F M Gribble
Journal:  Diabet Med       Date:  2008-08       Impact factor: 4.359
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.